Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

COVID-19 and Tuberculosis: Two Knives in a Sheath

Author(s): Kishore Kumar Meenakshi Sundaram, Attuluri Vamsi Kumar, Thomas Alphonsa, Sangeetha Rajendran, Krishnamurthy Rajamanickam, Alemtoshi, Vellingiri Balachandar, Pranjal Bharali, Bupesh Giridharan* and Konda Mani Saravanan*

Volume 3, Issue 5, 2022

Published on: 13 September, 2022

Article ID: e050722206645 Pages: 14

DOI: 10.2174/2666796703666220705144250

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has caused a global human outbreak, making it a more serious threat to human health than any other infectious disease. Coronavirus infectious disease 2019 (COVID-19) has severely affected the lifestyles of people around the world and caused high mortality throughout the world. In both pandemic and seasonal influenza, co-infection of COVID-19 with other diseases has been linked to worse outcomes. The literature revealed that it is characteristically associated with comorbidities such as hypertension, blood pressure, obesity, cardiovascular diseases, and other microbial infections. Furthermore, microbial coinfections worsen respiratory viral infections and are a common cause of death in influenza pandemics. Deplorably, Tuberculosis (TB) is also a dreadful lung infection and attains cytokine equilibrium with host cells to maintain the latent stage. Studies showed that human coronaviruses (hCoV) activate latent TB to an active state due to unregulated cytokine production, called a cytokine storm. The present review concisely discusses the reason and status of co-infection of COVID-19 with TB based on previous case reports, cohorts, and scientific studies. COVID-19 patients are prone to be infected with TB and vice-versa in TB-prone areas. The therapeutic opportunities for overcoming the COVID-19 induced cytokine storm have also been emphasized by the present clinical trial candidates. In conclusion, we recommend categorizing the patients based on their medical history and cured or latent TB patients should be particularly closely monitored. They should be tested for Interferon Gamma Release Assay (IGRA) regularly on and after COVID-19 infection.

Keywords: COVID-19, tuberculosis, coinfection, pandemic, cytokines, vaccines, microbial infections.

Graphical Abstract

[1]
Bell BP, Damon IK, Jernigan DB, et al. Overview, control strategies, and lessons learned in the CDC response to the 2014-2016 Ebola epidemic. MMWR Suppl 2016; 65(3): 4-11.
[http://dx.doi.org/10.15585/mmwr.su6503a2] [PMID: 27389903]
[2]
Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux B. Focus on Middle East respiratory syndrome coronavirus (MERS-CoV). Med Mal Infect 2020; 50(3): 243-51.
[http://dx.doi.org/10.1016/j.medmal.2019.10.004] [PMID: 31727466]
[3]
Hui DSC, Zumla A. Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect Dis Clin 2019; 33(4): 869-89.
[http://dx.doi.org/10.1016/j.idc.2019.07.001] [PMID: 31668196]
[4]
Musso D, Ko AI, Baud D. Zika virus infection - after the pandemic. N Engl J Med 2019; 381(15): 1444-57.
[http://dx.doi.org/10.1056/NEJMra1808246] [PMID: 31597021]
[5]
Zhang H, Saravanan KM, Yang Y, et al. Deep learning based drug screening for novel coronavirus 2019-nCov. Interdiscip Sci 2020; 12(3): 368-76.
[http://dx.doi.org/10.1007/s12539-020-00376-6] [PMID: 32488835]
[6]
Saravanan KM, Zhang H, Hossain MT, Reza MS, Wei Y. Deep learning-based drug screening for COVID-19 and case studies. In: Roy K, Ed. Methods in Pharmacology and Toxicology. New York: Humana 2021; pp. 631-60.
[http://dx.doi.org/10.1007/7653_2020_58]
[7]
Saravanan KM, Zhang H, Senthil R, et al. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. J Biomol Struct Dyn 2022; 40(5): 1970-8.
[http://dx.doi.org/10.1080/07391102.2020.1834457] [PMID: 33073712]
[8]
Cleaveland S, Laurenson MK, Taylor LH. Diseases of humans and their domestic mammals: Pathogen characteristics, host range and the risk of emergence. Philos Trans R Soc Lond B Biol Sci 2001; 356(1411): 991-9.
[http://dx.doi.org/10.1098/rstb.2001.0889] [PMID: 11516377]
[9]
Yan R, Zhang Y, Guo Y, Xia L, Zhou Q. Structural basis for the recognition of the 2019-NCoV by human ACE2. bioRxiv 2020; 2762.2020.02.19.956946.
[http://dx.doi.org/10.1101/2020.02.19.956946]
[10]
Perl TM, Price CS. Managing emerging infectious diseases: Should travel be the fifth vital sign? Ann Intern Med 2020; 172(8): 560-1.
[http://dx.doi.org/10.7326/M20-0643] [PMID: 32120386]
[11]
Zhang H, Yang Y, Li J, et al. A novel virtual screening procedure identifies pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLOS Comput Biol 2020; 16(12): e1008489.
[http://dx.doi.org/10.1371/journal.pcbi.1008489] [PMID: 33382685]
[12]
Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: Integrating health services and control efforts. Lancet Infect Dis 2013; 13(5): 436-48.
[http://dx.doi.org/10.1016/S1473-3099(13)70015-X] [PMID: 23531392]
[13]
Boffa J, Mhlaba T, Sulis G, et al. COVID-19 and tuberculosis in South Africa: A dangerous combination. S Afr Med J 2020; 110(5): 341-2.
[http://dx.doi.org/10.7196/SAMJ.2020.v110i5.14747] [PMID: 32657710]
[14]
Cohen K, Meintjes G. Management of individuals requiring ART and TB treatment. Curr Opin HIV AIDS 2010; 5: 61-9.
[http://dx.doi.org/10.1097/COH.0b013e3283339309] [PMID: 20046149]
[15]
Mzembe T, Mclean E, Khan PY, et al. Risk of Mycobacterium tuberculosis transmission in an antiretroviral therapy clinic. AIDS 2018; 32(16): 2417-21.
[http://dx.doi.org/10.1097/QAD.0000000000002006] [PMID: 30234604]
[16]
Kranzer K, Houben RMGJ, Glynn JR, Bekker L-G, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: A systematic review and meta-analysis. Lancet Infect Dis 2010; 10(2): 93-102.
[http://dx.doi.org/10.1016/S1473-3099(09)70326-3] [PMID: 20113978]
[17]
Liu Y, Bi L, Chen Y, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. medRxiv 2020.
[18]
Martin A, Baptiste JP, Krieger G. Respiratory infections: SARS and tuberculosis. Clin Occup Environ Med 2004; 4(1): 189-204.
[http://dx.doi.org/10.1016/j.coem.2003.10.006] [PMID: 15043370]
[19]
Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-Burden setting. PLoS One 2017; 12(1): e0169539.
[http://dx.doi.org/10.1371/journal.pone.0169539] [PMID: 28060926]
[20]
Lacerda TC, Souza FM, Prado TND, et al. Tuberculosis infection among primary health care workers. J Bras Pneumol 2017; 43(6): 416-23.
[http://dx.doi.org/10.1590/s1806-37562016000000211] [PMID: 29340489]
[21]
Berger ZD, Evans NG, Phelan AL, Silverman RD. COVID-19: Control measures must be equitable and inclusive. BMJ 2020; 368: m1141.
[http://dx.doi.org/10.1136/bmj.m1141] [PMID: 32198146]
[22]
Engelbrecht M, Rau A, Kigozi G, et al. Waiting to inhale: Factors associated with healthcare workers’ fears of occupationally-acquired tuberculosis (TB). BMC Infect Dis 2019; 19(1): 475.
[http://dx.doi.org/10.1186/s12879-019-4115-z] [PMID: 31138140]
[23]
Mor N. Resources for primary care providers to meet patients needs during the COVID-19 epidemic. COVID-19 2020; 1-21.
[24]
Sultan S, Lim JK, Altayar O, et al. AGA rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic. Gastroenterology 2020; 159(2): 739-758.e4.
[http://dx.doi.org/10.1053/j.gastro.2020.03.072] [PMID: 32247018]
[25]
Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol 2020; 13(2): 190-204.
[http://dx.doi.org/10.1038/s41385-019-0226-5] [PMID: 31772320]
[26]
Kim C, Park SH, Oh SY, et al. Comparison of chest CT findings in nontuberculous mycobacterial diseases vs. Mycobacterium tuberculosis lung disease in HIV-negative patients with cavities. PLoS One 2017; 12(3): e0174240.
[http://dx.doi.org/10.1371/journal.pone.0174240] [PMID: 28346488]
[27]
Roberts CA, Boylston A, Buckley L, Chamberlain AC, Murphy EM. Rib lesions and tuberculosis: The palaeopathological evidence. Tuber Lung Dis 1998; 79(1): 55-60.
[http://dx.doi.org/10.1054/tuld.1998.0005] [PMID: 10645442]
[28]
Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J 2011; 80(2): 84-90.
[PMID: 22347750]
[29]
Laveneziana P, Sesé L, Gille T. Pathophysiology of pulmonary function anomalies in COVID-19 survivors. Breathe 2021; 17(3): 210065.
[http://dx.doi.org/10.1183/20734735.0065-2021] [PMID: 35035546]
[30]
Choi YJ, Kwon DS, Kim T, et al. Low alanine aminotransferase as a risk factor for chronic obstructive pulmonary disease in males. Sci Rep 2021; 11(1): 14829.
[http://dx.doi.org/10.1038/s41598-021-94385-0] [PMID: 34290312]
[31]
Wood S, Harrison SE, Judd N, Bellis MA, Hughes K, Jones A. The impact of behavioural risk factors on communicable diseases: A systematic review of reviews. BMC Public Health 2021; 21(1): 2110.
[http://dx.doi.org/10.1186/s12889-021-12148-y] [PMID: 34789209]
[32]
Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: From epidemiology to pathophysiology. Eur Respir Rev 2018; 27(147): 170077.
[http://dx.doi.org/10.1183/16000617.0077-2017] [PMID: 29491034]
[33]
Borah P, Deb PK, Venugopala KN, et al. Tuberculosis: An update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host- directed therapies. Curr Top Med Chem 2021; 21(6): 547-70.
[http://dx.doi.org/10.2174/1568026621999201211200447] [PMID: 33319660]
[34]
Chai Q, Wang L, Liu CH, Ge B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol 2020; 17(9): 901-13.
[http://dx.doi.org/10.1038/s41423-020-0502-z] [PMID: 32728204]
[35]
Achkar JM, Chan J, Casadevall A. B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 2015; 264(1): 167-81.
[http://dx.doi.org/10.1111/imr.12276] [PMID: 25703559]
[36]
Guler R, Brombacher F. Host-directed drug therapy for tuberculosis. Nat Chem Biol 2015; 11(10): 748-51.
[http://dx.doi.org/10.1038/nchembio.1917] [PMID: 26379013]
[37]
Ahmed S, Raqib R, Guðmundsson GH, Bergman P, Agerberth B, Rekha RS. Host-directed therapy as a novel treatment strategy to overcome tuberculosis: Targeting immune modulation. Antibiotics 2020; 9(1): 21.
[http://dx.doi.org/10.3390/antibiotics9010021] [PMID: 31936156]
[38]
Huang Z, Su R, Deng Z, et al. Identification of differentially expressed circular RNAs in human monocyte derived macrophages response to Mycobacterium tuberculosis infection. Sci Rep 2017; 7(1): 13673.
[http://dx.doi.org/10.1038/s41598-017-13885-0] [PMID: 29057952]
[39]
Crilly NP, Ayeh SK, Karakousis PC. The new frontier of host-directed therapies for Mycobacterium avium complex. Front Immunol 2021; 11: 623119.
[http://dx.doi.org/10.3389/fimmu.2020.623119] [PMID: 33552087]
[40]
Szkuta PT. The role of neutrophils in mycobacterial infection in zebrafish. PhD Thesis, Department of Infection, Immunity and Cardiovascular Disease 2020.
[41]
Hu C. C. Immune response and interaction of MAIT cell and Vγ2Vδ2 T cell subsets in TB infection of primate. Thesis. University of Illinois at Chicago, Chicago, Illinois 2019.
[42]
Moreira AL, Tsenova L, Aman MH, et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 2002; 70(4): 2100-7.
[http://dx.doi.org/10.1128/IAI.70.4.2100-2107.2002] [PMID: 11895976]
[43]
Plantier L, Cazes A, Dinh-Xuan A-T, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev 2018; 27(147): 27.
[http://dx.doi.org/10.1183/16000617.0062-2017] [PMID: 29367408]
[44]
Li Q, Xie Y, Cui Z, et al. Activation of hypoxia-inducible factor 1 (Hif-1) enhanced bactericidal effects of macrophages to Mycobacterium tuberculosis. Tuberculosis (Edinb) 2021; 126: 102044.
[http://dx.doi.org/10.1016/j.tube.2020.102044] [PMID: 33383382]
[45]
Baay-Guzman GJ, Duran-Padilla MA, Rangel-Santiago J, et al. Dual role of hypoxia-inducible factor 1 α in experimental pulmonary tuberculosis: Its implication as a new therapeutic target. Future Microbiol 2018; 13: 785-98.
[http://dx.doi.org/10.2217/fmb-2017-0168] [PMID: 29848058]
[46]
Hammond FR, Lewis A, Elks PM. If it’s not one thing, HIF’s another: Immunoregulation by hypoxia inducible factors in disease. FEBS J 2020; 287(18): 3907-16.
[http://dx.doi.org/10.1111/febs.15476] [PMID: 32633061]
[47]
Oehlers SH, Hortle E, Cook KM. A zebrafish model of tuberculosis comorbidity and the effects of HIF-activating intervention. FEBS J 2020; 287(18): 3917-20.
[http://dx.doi.org/10.1111/febs.15463] [PMID: 32652856]
[48]
Resende M, Ferreira CM, Barbosa AM, et al. Myeloid HIF-1α regulates pulmonary inflammation during experimental Mycobacterium tuberculosis infection. Immunology 2020; 159(1): 121-9.
[http://dx.doi.org/10.1111/imm.13131] [PMID: 31606895]
[49]
Hackett E. microRNA-21 limits macrophage responses to Mycobacterium tuberculosis. Thesis. Trinity College Dublin. School of Biochemistry & Immunology 2019.
[50]
Rebrova EM. Cell wall remodeling proteins in Mycobacterium tuberculosis: Structure, function and inhibition. Sweden: Karolinska Institutet 2017.
[51]
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts 2018; 9(1): 64-79.
[http://dx.doi.org/10.1515/bmc-2018-0007] [PMID: 29856726]
[52]
Mezouar S, Mege JL. Changing the paradigm of IFN-γ at the interface between innate and adaptive immunity: Macrophage-derived IFN-γ. J Leukoc Biol 2020; 108(1): 419-26.
[http://dx.doi.org/10.1002/JLB.4MIR0420-619RR] [PMID: 32531848]
[53]
Wang C, Lu J, Du W, et al. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent Mycobacterium tuberculosis infection. Vaccine 2019; 37(32): 4477-84.
[http://dx.doi.org/10.1016/j.vaccine.2019.06.078] [PMID: 31266673]
[54]
Blanchett S, Tsai CJY, Sandford S, et al. Intranasal immunization with Ag85B peptide 25 displayed on Lactococcus lactis using the PilVax platform induces antigen-specific B- and T-cell responses. Immunol Cell Biol 2021; 99(7): 767-81.
[http://dx.doi.org/10.1111/imcb.12462] [PMID: 33866609]
[55]
Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections. Immunol Rev 2021; 301(1): 62-83.
[http://dx.doi.org/10.1111/imr.12951] [PMID: 33565103]
[56]
Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 2018; 233(9): 6425-40.
[http://dx.doi.org/10.1002/jcp.26429] [PMID: 29319160]
[57]
Rook GAW, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: Implications for vaccine design. Trends Immunol 2004; 25(9): 483-8.
[http://dx.doi.org/10.1016/j.it.2004.06.005] [PMID: 15324741]
[58]
Sharma S, Bose M. Role of cytokines in immune response to pulmonary tuberculosis. Asian Pac J Allergy Immunol 2001; 19(3): 213-9.
[PMID: 11826917]
[59]
Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GAW. Lung remodeling in pulmonary tuberculosis. J Infect Dis 2005; 192(7): 1201-9.
[http://dx.doi.org/10.1086/444545] [PMID: 16136463]
[60]
Krug S, Parveen S, Bishai WR. Host-directed therapies: Modulating inflammation to treat tuberculosis. Front Immunol 2021; 12: 660916.
[http://dx.doi.org/10.3389/fimmu.2021.660916] [PMID: 33953722]
[61]
Chakrabarti S, Patel KD. Matrix Metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 2005; 31(6): 599-621.
[http://dx.doi.org/10.1080/019021490944232] [PMID: 16019990]
[62]
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. Cells 2020; 9(5): 1313.
[http://dx.doi.org/10.3390/cells9051313] [PMID: 32466129]
[63]
Seele PP. Characterisation of dysregulated proteins in macrophages infected with Mycobacterium smegmatis focusing on matrix metalloproteases and their effectors. PhD Dissertation Faculty of Health Sciences, Department of Integrative Biomedical Sciences (IBMS) 2019.
[64]
Ghafouri-Fard S, Abak A, Shoorei H, et al. Interaction between non-coding RNAs and Toll-like receptors. Biomed Pharmacother 2021; 140: 111784.
[http://dx.doi.org/10.1016/j.biopha.2021.111784] [PMID: 34087695]
[65]
Gauba K, Gupta S, Shekhawat J, Sharma P, Yadav D, Banerjee M. Immunomodulation by epigenome alterations in Mycobacterium tuberculosis infection. Tuberculosis 2021; 128: 102077.
[http://dx.doi.org/10.1016/j.tube.2021.102077] [PMID: 33812175]
[66]
Rohlwink UK, Walker NF, Ordonez AA, et al. Matrix metalloproteinases in pulmonary and central nervous system tuberculosis-A review. Int J Mol Sci 2019; 20(6): 1350.
[http://dx.doi.org/10.3390/ijms20061350] [PMID: 30889803]
[67]
Davis AG, Donovan J, Bremer M, et al. Host directed therapies for tuberculous meningitis. Wellcome Open Res 2021; 5: 292.
[http://dx.doi.org/10.12688/wellcomeopenres.16474.2] [PMID: 35118196]
[68]
Sabir N, Hussain T, Mangi MH, Zhao D, Zhou X. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif 2019; 52(4): e12649.
[http://dx.doi.org/10.1111/cpr.12649] [PMID: 31199047]
[69]
Oikonomidi S, Kostikas K, Tsilioni I, Tanou K, Gourgoulianis KI, Kiropoulos TS. Matrix metalloproteinases in respiratory diseases: From pathogenesis to potential clinical implications. Curr Med Chem 2009; 16(10): 1214-28.
[http://dx.doi.org/10.2174/092986709787846587] [PMID: 19355880]
[70]
Mohan V, Talmi-Frank D, Arkadash V, Papo N, Sagi I. Matrix metalloproteinase protein inhibitors: Highlighting a new beginning for metalloproteinases in medicine. Met Med 2016; 3: 31-47.
[71]
D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol 2013; 20(3): 319-27.
[http://dx.doi.org/10.1128/CVI.00636-12] [PMID: 23283640]
[72]
Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014; 5: 58.
[http://dx.doi.org/10.3389/fimmu.2014.00058] [PMID: 24600449]
[73]
Duncan SA, Baganizi DR, Sahu R, Singh SR, Dennis VA. SOCS proteins as regulators of inflammatory responses induced by bacterial infections: A review. Front Microbiol 2017; 8: 2431.
[http://dx.doi.org/10.3389/fmicb.2017.02431] [PMID: 29312162]
[74]
Gao Y, Zhao H, Wang P, Wang J, Zou L. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases. Scand J Immunol 2018; 88(6): e12727.
[http://dx.doi.org/10.1111/sji.12727] [PMID: 30341772]
[75]
Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. J Infect 2020; 11: 1708.
[PMID: 32283152]
[76]
Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 2020; 14: 1022.
[http://dx.doi.org/10.3332/ecancer.2020.1022] [PMID: 32256705]
[77]
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-74.
[http://dx.doi.org/10.1038/s41577-020-0311-8] [PMID: 32346093]
[78]
Ambika S, Manojkumar Y, Arunachalam S, et al. Biomolecular interaction, anti-cancer and anti-angiogenic properties of cobalt(III) Schiff base complexes. Sci Rep 2019; 9(1): 2721.
[http://dx.doi.org/10.1038/s41598-019-39179-1] [PMID: 30804454]
[79]
Polito AJ, Proud D. Epithelia cells as regulators of airway inflammation. J Allergy Clin Immunol 1998; 102(5): 714-8.
[http://dx.doi.org/10.1016/S0091-6749(98)70008-9] [PMID: 9867498]
[80]
Stark JM, Godding V, Sedgwick JB, Busse WW. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. J Immunol 1996; 156(12): 4774-82.
[PMID: 8648124]
[81]
Yoshikawa T, Hill T, Li K, Peters CJ, Tseng C-TK. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol 2009; 83(7): 3039-48.
[http://dx.doi.org/10.1128/JVI.01792-08] [PMID: 19004938]
[82]
Holt PG, Strickland DH, Wikström ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008; 8(2): 142-52.
[http://dx.doi.org/10.1038/nri2236] [PMID: 18204469]
[83]
Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat Immunol 2015; 16(1): 27-35.
[http://dx.doi.org/10.1038/ni.3045] [PMID: 25521682]
[84]
Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol 2009; 21(4): 378-84.
[http://dx.doi.org/10.1016/j.coi.2009.06.004] [PMID: 19646851]
[85]
Liu Y, Zhang C, Huang F, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev 2020; 7(6): 1003-11.
[http://dx.doi.org/10.1093/nsr/nwaa037] [PMID: 34676126]
[86]
Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: A review of virus-host interactions. Diseases 2016; 4(3): 26.
[http://dx.doi.org/10.3390/diseases4030026] [PMID: 28933406]
[87]
Wu D, Lin Z, Zhang S, Cao F, Liang D, Zhou X. Decreased hemoglobin concentration and iron metabolism disorder in periodontitis: Systematic review and meta-analysis. Front Physiol 2020; 10: 1620.
[http://dx.doi.org/10.3389/fphys.2019.01620] [PMID: 32082180]
[88]
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020; 7: 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0]
[89]
Cao X. COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20(5): 269-70.
[http://dx.doi.org/10.1038/s41577-020-0308-3] [PMID: 32273594]
[90]
Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17(5): 533-5.
[http://dx.doi.org/10.1038/s41423-020-0402-2] [PMID: 32203188]
[91]
Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: From beneficial to detrimental effects on bone marrow output. Front Immunol 2016; 7: 364.
[http://dx.doi.org/10.3389/fimmu.2016.00364] [PMID: 27695457]
[92]
Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun 2020; 12(1): 4-20.
[http://dx.doi.org/10.1159/000503030] [PMID: 31610541]
[93]
Low JGH, Lee CC, Leo YS, Low JG, Lee CC, Leo YS. Severe acute respiratory syndrome and pulmonary tuberculosis. Clin Infect Dis 2004; 38(12): e123-5.
[http://dx.doi.org/10.1086/421396] [PMID: 15227635]
[94]
Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: A double-edged sword? Lancet 2020; 395(10230): 1111.
[http://dx.doi.org/10.1016/S0140-6736(20)30691-7] [PMID: 32220278]
[95]
Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: What can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020; 38(2): 337-42.
[PMID: 32202240]
[96]
Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in longterm Liver transplant patients: Preliminary experience from an Italian Transplant Centre in Lombardy. lancet Gastroenterol Hepatol 2020; 2468-1253(20): 30116-23.
[97]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[98]
Wu B, Huang C, Kato-Maeda M, et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2008; 126(2): 202-10.
[http://dx.doi.org/10.1016/j.clim.2007.09.009] [PMID: 18032114]
[99]
Alvarez I, Rovetta A, Hernández Del Pino R, et al. IL-9-producing cells promote Th1 responses against Mycobacterium tuberculosis. (P3015). J Immunol 2013; 190: 55-8.
[100]
Mendy J, Jarju S, Heslop R, Bojang AL, Kampmann B, Sutherland JS. Changes in Mycobacterium tuberculosis-specific immunity with influenza co-infection at time of TB diagnosis. Front Immunol 2019; 9: 3093.
[http://dx.doi.org/10.3389/fimmu.2018.03093] [PMID: 30662443]
[101]
Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. Cytokine polarization in miliary and pleural tuberculosis. J Clin Immunol 2002; 22(6): 345-52.
[http://dx.doi.org/10.1023/A:1020604331886] [PMID: 12462334]
[102]
Hu W, Yen YT, Singh S, Kao CL, Wu-Hsieh BA. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol 2012; 25(4): 277-88.
[http://dx.doi.org/10.1089/vim.2011.0099] [PMID: 22876772]
[103]
Alosaimi B, Hamed ME, Naeem A, et al. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine 2020; 126: 154895.
[http://dx.doi.org/10.1016/j.cyto.2019.154895] [PMID: 31706200]
[104]
Moideen K, Kumar NP, Nair D, Banurekha VV, Bethunaickan R, Babu S. Heightened systemic levels of neutrophil and eosinophil granular proteins in pulmonary tuberculosis and reversal following treatment. Infect Immun 2018; 86(6): e00008-18.
[http://dx.doi.org/10.1128/IAI.00008-18] [PMID: 29632246]
[105]
Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4<Sup>+</Sup> T cells are important in control of SARS-CoV infection. J Virol 2010; 84: 1289-301.
[106]
Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005; 171(8): 850-7.
[http://dx.doi.org/10.1164/rccm.200407-857OC] [PMID: 15657466]
[107]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[108]
McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020; 19: 102537.
[http://dx.doi.org/10.1016/j.autrev.2020.102537] [PMID: 32251717]
[109]
Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 2001; 65(1): 131-50.
[http://dx.doi.org/10.1128/MMBR.65.1.131-150.2001] [PMID: 11238989]
[110]
Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J Infect Dis 2014; 209(9): 1331-42.
[http://dx.doi.org/10.1093/infdis/jit504] [PMID: 24065148]
[111]
Krupa A, Fol M, Dziadek BR, et al. Binding of CXCL8/IL-8 to Mycobacterium tuberculosis modulates the innate immune response. Mediators Inflamm 2015; 2015: 124762.
[http://dx.doi.org/10.1155/2015/124762] [PMID: 26300588]
[112]
Cinatl J Jr, Michaelis M, Morgenstern B, Doerr HW. High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells. Int J Mol Med 2005; 15(2): 323-7.
[http://dx.doi.org/10.3892/ijmm.15.2.323] [PMID: 15647850]
[113]
Spiegel M, Weber F. Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus. Virol J 2006; 3: 17.
[http://dx.doi.org/10.1186/1743-422X-3-17] [PMID: 16571117]
[114]
Crawford A, Angelosanto JM, Nadwodny KL, Blackburn SD, Wherry EJ. A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog 2011; 7(7): e1002098.
[http://dx.doi.org/10.1371/journal.ppat.1002098] [PMID: 21814510]
[115]
Hussain R, Ansari A, Talat N, Hasan Z, Dawood G. CCL2/MCP-I genotype-phenotype relationship in latent tuberculosis infection. PLoS One 2011; 6(10): e25803.
[http://dx.doi.org/10.1371/journal.pone.0025803] [PMID: 21991356]
[116]
Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123(2): 233-8.
[http://dx.doi.org/10.1046/j.1365-2249.2001.01401.x] [PMID: 11207653]
[117]
Ellner JJ. Regulation of the human immune response during tuberculosis. J Lab Clin Med 1997; 130(5): 469-75.
[http://dx.doi.org/10.1016/S0022-2143(97)90123-2] [PMID: 9390634]
[118]
Ng MW, Zhou G, Chong WP, et al. The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infect Dis 2007; 7: 50.
[http://dx.doi.org/10.1186/1471-2334-7-50] [PMID: 17540042]
[119]
Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016; 13(1): 3-10.
[http://dx.doi.org/10.1038/cmi.2015.74] [PMID: 26189369]
[120]
Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68(5): 479-503.
[http://dx.doi.org/10.1007/s00228-011-1161-x] [PMID: 22105373]
[121]
Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol 2019; 9: 1186.
[http://dx.doi.org/10.3389/fonc.2019.01186] [PMID: 31788449]
[122]
Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol 2016; 2016: 2389038.
[http://dx.doi.org/10.1155/2016/2389038] [PMID: 27843657]
[123]
Lescuyer S, Ledoux MP, Gravier S, et al. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis 2019; 80: 134-6.
[http://dx.doi.org/10.1016/j.ijid.2019.01.002] [PMID: 30639623]
[124]
Honore PM, Hoste E, Molnár Z, et al. Cytokine removal in human septic shock: Where are we and where are we going? Ann Intensive Care 2019; 9(1): 56.
[http://dx.doi.org/10.1186/s13613-019-0530-y] [PMID: 31089920]
[125]
İnce C. Blood transfusions correct anemia and improve tissue oxygenation in surgical and critically ill patients. Turk J Anaesthesiol Reanim 2017; 45(3): 119-21.
[http://dx.doi.org/10.5152/TJAR.2017.08051] [PMID: 28751998]
[126]
Meybohm P, Lindau S, Treskatsch S, et al. Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial. Trials 2019; 20(1): 101.
[http://dx.doi.org/10.1186/s13063-019-3200-3] [PMID: 30717805]
[127]
Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: An overview. Trop Med Infect Dis 2020; 5(3): 5.
[http://dx.doi.org/10.3390/tropicalmed5030123] [PMID: 32722014]
[128]
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: Lessons from the past. Front Immunol 2020; 11: 1949.
[http://dx.doi.org/10.3389/fimmu.2020.01949] [PMID: 32849654]
[129]
Tadolini M, Garcia-Garcia JM, Blanc F-X, et al. On tuberculosis and COVID-19 co-infection. Eur Respir J 2020; 56: 2002328.
[130]
Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: Pathogenic mechanisms and therapeutic implications. Ther Adv Respir Dis 2020; 14: 1753466620933508.
[http://dx.doi.org/10.1177/1753466620933508] [PMID: 32539627]
[131]
Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr 2020; 14(5): 1439-43.
[http://dx.doi.org/10.1016/j.dsx.2020.07.034] [PMID: 32755848]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy